Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 802 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacological Intervention Clear all
Withdrawn Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003517
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
Interventions
antineoplaston A10, antineoplaston AS2-1, bicalutamide, flutamide, leuprolide acetate, alternative product therapy, antiandrogen therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy, endocrine therapy, hormone therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 9, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

NCT00492440
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
recombinant interleukin-7, gene expression analysis, polymerase chain reaction, protein expression analysis, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Biological · Genetic · Other
Lead sponsor
Cytheris SA
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02518555
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in Adults With Chronic Cough

NCT07566117
View directory record Official record
Conditions
Chronic Cough
Interventions
Acceptance and Commitment Therapy (ACT)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01912625
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Trametinib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Rochester, Minnesota • Cleveland, Ohio • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Local Anesthetic Dose on Interscalene Block

NCT01701115
View directory record Official record
Conditions
Shoulder Arthroscopy, Interscalene Block
Interventions
Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block, Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block, Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine), Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 9, 2026, 2:58 AM EDT
Withdrawn Phase 4 Interventional

Adaptive Response to Intervention (RTI) for Students With ADHD

NCT03511976
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 9, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

NCT03320642
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Itacitinib, Calcineurin inhibitor
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 9, 2026, 2:58 AM EDT
Not listed Not applicable Interventional

Simultaneously Targeting Obesity and Pain: The STOP Trial

NCT02100995
View directory record Official record
Conditions
Obesity, Chronic Pain
Interventions
Intervention Simultaneously Targeting Obesity and Pain, Weight Loss/Weight Self-Management, Chronic Pain Self-Management
Behavioral
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 9, 2026, 2:58 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

NCT01970527
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
Biological · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 9, 2026, 2:58 AM EDT
Terminated Not applicable Interventional

Cervical Spine Focused Treatment for Patients With Persistent Concussion Symptoms and Neck Pain

NCT06616272
View directory record Official record
Conditions
Brain Concussion, Neck Pain
Interventions
Cervical rehabilitation, Standard Concussion Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

Measuring Analgesic Interventions

NCT03794362
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Julia Finkel
Other
Eligibility
7 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Early Phase 1 Interventional

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

NCT00436410
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions
colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
Biological · Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

NCT05089851
View directory record Official record
Conditions
Wrinkles, Photoaging, Fine Lines
Interventions
Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Combination Product
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 9, 2026, 2:58 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529
View directory record Official record
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Withdrawn No phase listed Observational

Catheter Ablation for Atrial Fibrillation and Heart Failure

NCT01082601
View directory record Official record
Conditions
Congestive Heart Failure, Atrial Fibrillation, Arrhythmia
Interventions
Pulmonary Vein Isolation (PVI)
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Ridgewood, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 9, 2026, 2:58 AM EDT
Not yet recruiting Phase 4 Interventional

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

NCT06740812
View directory record Official record
Conditions
Nausea and Vomiting, Nausea, Vomiting
Interventions
Fosaprepitant for Injection, Metoclopramide Injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection

NCT01419067
View directory record Official record
Conditions
Craniopharyngioma
Interventions
Radical Surgery or Limited Surgery, Proton Therapy, ^1^8F-fluorodeoxyglucose, ^1^1C-methionine
Procedure · Device · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
2
States / cities
Jacksonville, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Recruiting Not applicable Interventional

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

NCT06854458
View directory record Official record
Conditions
Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
Interventions
Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment
Diagnostic Test · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Not applicable Interventional Results available

Tailored Drug Titration Using Artificial Intelligence

NCT04223934
View directory record Official record
Conditions
Hypertension
Interventions
optima4BP
Other
Lead sponsor
Optima Integrated Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Not applicable Interventional

DYNA EMBOLIZATION - Pilot Study of IV Dyna CT and CBV Imaging Techniques

NCT03528200
View directory record Official record
Conditions
Brain Lesions
Interventions
Contrast
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 9, 2026, 2:58 AM EDT
Not yet recruiting Phase 4 Interventional

Second Line Endovascular Treatment in Acute DVT

NCT06486181
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Thrombolysis/Thrombectomy
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 9, 2026, 2:58 AM EDT
Completed Phase 4 Interventional

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure

NCT01863511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
loop diuretic, tolvaptan, ultrafiltration
Drug · Procedure
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 9, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT01071564
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 9, 2026, 2:58 AM EDT